| 영문 | beta-blocker | 한글 | 베타차단제 |
|---|---|---|---|
| 설명 | 베타-수용체(1과 2에 관계없이)의 기능을 억제시키는 약물로 이 수용체가 매개하여 생기는 신체의 변화를 억제한다. Propranolol이 좋은 예이다. |
||
| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | angiotensin | 한글 | 안지오텐신 |
|---|---|---|---|
| 설명 | 콩팥에서 신장의 혈류와 혈압을 감지하는 세포인 치밀반점(macula densa)과 토리곁세포(JG cell)에서 혈류와 혈압의 저하가 있을 경우에 레닌이라는 물질이 분비되게 된다. 이 레닌이라는 물질은 혈중에 존재하는 안지오텐신이라는 물질을 안지오텐신 I으로 변화시키고 이 안지오텐신 I이라는 물질은 안지오텐신 I 전환효소에 의해서 안지오텐신II라는 물질로 된다. 안지오텐신과 안지오텐신 I이라는 물질은 그 작용이 거의 없지만 안지오텐신 II라는 물질은 강력하게 혈관수축을 시키고 이로 인해서 혈압의 상승을 가져오며 동시에 부신을 자극하여 알도스테론을 분비하게 한다. 안지오텐신이란 혈관을 수축시키고 알도스테론의 분비를 유도함으로써 혈압의 상승을 가져오는 물질이다. 그리고 그 작용은 레닌-안지오텐신-알도스테론으로 이어지는 체계에 의해서 조절되고 이루어진다. |
||
| Ca2+-blocker | calcium channel blocker |
|---|---|
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
| RAR | rapidly adapting receptor; rat insulin receptor; retinoic acid receptor; right arm reclining; right ... |
| BB | bad breath; bed bath; beta blockade, beta blocker; BioBreeding [rat]; blanket bath; blood bank; bloo... |
| BHAT | Beta Blocker Heart Attack Trial |
| ARB | angiotensin receptor blocker |
|---|---|
| ARB | Angiotensin II receptor blocker |
| BHAT | Beta-Blocker Heart Attack Trial |
| CCB | Calcium channel blocker |
| CEB | Calcium entry blocker |
| alpha-blocker | An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension. Synonym: alpha-blocker. (05 Mar 2000) |
|---|---|
| beta-blocker | <pharmacology> A large group of medications that act to block specific receptors in the nervous system. A drug that induces adrenergic blockade at either á1 or á2 adrenergic receptors or at both. The effect of beta-blockade results in slowing of the heart rate, reduction in blood pressure and reduced anxiety. Beta-blockers are used in the treatment of angina, heart arrhythmias, high blood pressure, mitral valve prolapse and other conditions. (06 Oct 1997) |
| blocker | 1. An instrument used to obstruct a passage. See: blocking agent. (05 Mar 2000) |
| calcium channel-blocker | <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools. Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms. Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent. (12 May 2002) |
| medication, beta-blocker | Drugs that antagonise the action of adrenaline (a beta adrenergic substance) and relieve stress to the heart muscle. Beta-blockers are often used to slow the heart rate or lower the blood pressure. (12 Dec 1998) |
| H2 blocker | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
| angiotensin | <hormone> A family of oligopeptides ranging in size from angiotensin precursors with 14 amino acids to the active vasoconstrictor angiotensin II with 8 amino acids, or their analogs or derivatives. The amino acid content varies with the species and changes in that content produce antagonistic or inactive compounds. Angiotensinogen (renin substrate) is a 60 kD polypeptide released from the liver and cleaved in the circulation by renin to form the biologically inactive decapeptide angiotensin I. This is in turn cleaved to form active angiotensin II by Angiotensin-converting Enzyme (ACE). Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. (12 Aug 2000) |
| angiotensin amide | <chemical> 1-l-asparagine-5-l-valine-angiotensin II. The octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction. Pharmacological action: vasoconstrictor agents. Chemical name: Angiotensin II, 1-L-asparagine-5-L-valine- (12 Dec 1998) |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| angiotensin-converting enzyme secretase | <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline Registry number: EC 3.4.99.- Synonym: ace secretase (26 Jun 1999) |
| angiotensin I | <chemical> The decapeptide precursor of angiotensin II, generated by the action of renin on angiotensinogen. It has limited pharmacologic activity. Chemical name: Angiotensin I (12 Dec 1998) |
| angiotensin II | <chemical> The active form of angiotensin. An octapeptide found in blood, it is synthesised from angiotensin I and quickly destroyed. Angiotensin II causes profound vasoconstriction with resulting increase in blood pressure. The clinically and experimentally used bovine form has valine in position 5 where the human form has isoleucine. Pharmacological action: vasoconstrictor agents. Chemical name: Angiotensin II (12 Dec 1998) |
| angiotensin III | <chemical> A heptapeptide formed by the enzymatic hydrolysis of angiotensin II. It has greater activity than angiotensin II for stimulating aldosterone synthesis and in the release of prostaglandins but only 20% of the pressor activity. Chemical name: Angiotensin II, 1-de-L-aspartic acid- (12 Dec 1998) |
| angiotensin I (Phe 8-His 9) hydrolase | <enzyme> Cleaves the cooh-terminal dipeptide his(9)-leu(10) from the decapeptide angiotensin i Registry number: EC 3.4.15.- Synonym: atypical angiotensin-converting enzyme (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|